[1] Gambato M,Pérez-del-Pulgar S,Hedskog C,et al.Hepatitis C virus RNA persists in liver explants of most patients awaiting liver transplantation treated with an interferonfree regimen.Gastroenterology,2016,151:633-636.
[2] Manns M,Samuel D,Gane EJ,et al.Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:a multicentre,open-label,randomised,phase 2 trial.Lancet Infect Dis,2016,16:685-697.
[3] Curry MP,O′Leary JG,Bzowej N,et al.Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.N Engl J Med,2015,373:2618-2628.
[4] Welker MW,Luhne S,Lange CM,et al.Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.J Hepatol,2016,64:790-799.
[5] Dyson JK,Hutchinson J,Harrison L,et al.Liver toxicity associated with sofosbuvir,an NS5A inhibitor and ribavirin use.J Hepatol,2016,64:234-238. |
